Weekly News Round-Up – 14/8/20


In the news this week, the race for a vaccine begins to near its conclusion as the U.S. and U.K. continue to buy up supplies of promising vaccines, and Moderna comes under criticism for its steep prices that make the customer ‘pay twice’. In other news, almost 750,000 COVID tests have been recalled in the U.K. over safety.
U.K. REACHES DEAL FOR 90 MILLION DOSES OF COVID-19 VACCINES – The U.K. government has secured early access to two coronavirus vaccines for its stockpile. These come from J&J’s Jansson and US biotech Novavax. These purchases bring the country’s reserve doses to 340 million across six experimental vaccines. The vaccines will be delivered to the UK halfway through 2021 if they’re proven safe and effective.
MODERNA WINS MAJOR DEAL AS ‘TAXPAYER FUNDED’ COVID-19 VACCINE COMES UNDER CRITICISM – Moderna has reached a $1.5 billion deal with the U.S. government to deliver 100 million doses of its mRNA vaccine candidate, should it prove successful in late-stage testing. An option for another 400 million doses is included in the deal. A two-dose regimen of the vaccine is set to charge $30.50, the highest of the ‘Operation Warp Speed’ companies. This has raised criticisms that the company is using tax-payer money to fund 100% of its research and making the country ‘pay twice’.
ALMOST 750,000 U.K. COVID TESTS RECALLED OVER SAFETY CONCERNS – Up to 750,000 unused COVID-19 tests from diagnostics company Randox have been recalled over safety concerns. The government has commissioned a lab to determine whether the sterility of one supplier of Randox swabs, according to international standards.
In other news:
Clinical Trials
J&J and Moderna falling behind in race for COVID vaccine
Manufacturing
Celleron buys licence to develop and manufacturer Roche’s rare cancer drug emactuzumab
Pfizer to manufacture Gilead’s remdesivir
That’s all for now. See you next week!
Joshua Neil, Editor
Proventa International
To ensure you remain up-to-date on the latest in clinical development, sign up for Proventa International’s online Biomanufacturing Strategy Meeting 2020.

How to Reduce the Cost of Clinical Trial Supply Chain While Maintaining Quality and Efficiency
Clinical trial supply chain is a critical component of drug development, ensuring that drugs are available for testing, regulatory approval, and distribution. However, managing this supply chain can be challenging, with factors such as cost, quality, and efficiency all coming...
2 weeks agoHow to Reduce the Cost of Clinical Trial Supply Chain While Maintaining Quality and Efficiency
Clinical trial supply chain is a critical component of drug development, ensuring that drugs are available for testing, regulatory approval, and distribution. However, managing this supply chain can be challenging, with factors such as cost, quality, and efficiency all coming...
2 weeks ago
RNA Therapeutics: The World’s First mRNA Malaria Vaccine
Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....
2 years agoRNA Therapeutics: The World’s First mRNA Malaria Vaccine
Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....
2 years ago
Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years agoRaising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years ago